RecruitingNot ApplicableNCT06755866
DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Sponsor
Yunnan Cancer Hospital
Enrollment
135 participants
Start Date
Nov 26, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria4
- Be 18 years of age and older;
- First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy;
- The clinical stage is cT1b\~cT2N+; or the clinical stage is cT3\~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer);
- There are no contraindications to MRI examination
Exclusion Criteria4
- Have other primary tumors;
- The image quality does not meet the diagnostic criteria;
- Those who do not cooperate with the inspection;
- Patients who have received prior chemoradiotherapy
Interventions
DIAGNOSTIC_TESTThe application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer
Chest MRI scan outside of standard treatment options
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06755866
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994443 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597243 locations
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT0721770410 locations